|
Temozolomide (TMZ) Clinical Trials
11 actively recruiting trials across 5 locations
No change since July 2026
Also known as: TMZ, Temodal, Temodar
Pipeline
Phase 1: 1Phase 2: 4Phase 1/2: 6
Top Sponsors
- University of Birmingham1
- Theodore Laetsch1
- The First Affiliated Hospital of Zhengzhou University1
- Sun Yat-sen University1
- Nationwide Children's Hospital1
Indications
- Cancer11
- Glioblastoma Multiforme (GBM)2
- Relapsed Neuroblastoma2
- Glioma2
- Relapsed/Refractory Glioma1
Other6 trials
Birmingham, Alabama1 trial
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
Phase 2
La Jolla, California1 trial
Los Angeles, California1 trial
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Cedars-Sinai Medical Center
Phase 1/2
Aurora, Colorado1 trial
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Children's Hospital Colorado
Phase 2
Chicago, Illinois1 trial
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Ann & Robert H. Lurie Children's Hospital of Chicago
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.